Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) January 26, 2011
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
| Massachusetts | 1-14041 | 04-2882273 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 400 Wood Road | 02184 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code 781-848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Table of Contents
Item 5.02(c) Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers
On January 26, 2011, Haemonetics Corporation announced that the Board of Directors elected Paul M.
Black to join its Board effective immediately. Mr. Black will serve on the Board’s Audit and
Compensation Committees, also effective immediately.
Mr. Black will receive the standard retainers and meeting fees payable to non-employee directors of
the company, as described in the company’s Proxy Statement dated June 17, 2010. Also pursuant to
these arrangements, Mr. Black will receive equity compensation valued at $200,000, half of which is
granted as 6,002 shares in non-qualified stock options and half as 1,691 shares of restricted stock
units. These shares will vest on the one year anniversary of the grant date.
Item 7.01 Regulation FD Disclosure.
The company’s press release announcing the election of Mr. Black is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
| (c) | Exhibits |
99.1: Press Release of Haemonetics Corporation dated January 26, 2011 announcing the election of
Paul M. Black to join Haemonetics Board of Directors.
2
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
HAEMONETICS CORPORATION (Registrant) |
||||
| Date: January 26, 2011 | /s/ Susan Hanlon | |||
| Susan Hanlon, VP Finance | ||||
Table of Contents
EXHIBIT INDEX
| 99.1 | Press Release issued by Haemonetics Corporation on January 26, 2011 announcing the election of Paul M. Black to join Haemonetics Board of Directors. |
Exhibit 99.1
FOR RELEASE:
|
CONTACT: | |||
Date
|
January 26, 2011 | Bryanne Salmon | ||
Time
|
4:00 pm Eastern | Tel. (781) 356-9613 | ||
| bsalmon@haemonetics.com | ||||
Paul M. Black Joins Haemonetics Board of Directors
Braintree,
MA, January 26, 2011 — Haemonetics Corporation (NYSE:HAE) announced today that the Board
of Directors elected Black to join its Board effective immediately.
Mr. Black, age 52, spent 13 years with Cerner Corporation, a publically traded global provider of
healthcare information technology solutions. He retired as Cerner’s Chief Operating Officer in
2007. Prior to Cerner, Black was with IBM from 1982 to 1994, in a number of senior sales and
professional services leadership positions.
Mr. Black currently serves on the Boards at Connextions, Inc., and Saepio Technologies, Inc.,
private companies with enterprise wide, integrated software and services information technology
offerings, as well as the Board Chairman of Truman Medical Centers, a two hospital not-for-profit
acute-care health system located in Kansas City.
Black is an Operating Executive for Genstar Capital, LLC, a San Francisco-based private equity firm
that invests in leading middle-market companies as well as an Advisor to New Mountain’s debt
effort, Guardian, which was established in 2008 to purchase debt securities.
Mr. Black has a BS degree from Iowa State University and an MBA from the University of Iowa.
Ron Gelbman, Lead Director of Haemonetics’ Board said, “Paul’s deep knowledge and experience
scaling clinical information management systems to deliver clinical benefits and cost savings make
him uniquely qualified to help guide the Company as we pursue blood management solutions that are
leveraged through clinical information management systems.”
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood
management solutions for our customers. Together, our devices and consumables, information
technology platforms, and consulting services deliver a suite of business solutions to help our
customers improve clinical outcomes and reduce the cost of healthcare for blood collectors,
hospitals, and patients around the world. Our technologies address important medical markets:
blood and plasma component collection, the surgical suite, and hospital transfusion services. To
learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
Haemonetics Corporation • 400 Wood Road • Braintree, MA 02184 USA